F11 and hematocrit: Genetically predicted lower levels of FXI were nominally associated with the risk of HT after r-tPA treatment (OR, 0.87; 95% CI, 0.75–1.00; P = .05), with consistent results across sensitivity methods (Supplementary Table S8 and Supplementary Figure S1), but this association was not significant after correction for multiple comparisons.